EVANSTON, Illinois–(BUSINESS WIRE)– De wereldwijde professionele dienstverlener ZS heeft vandaag aangekondigd dat het een strategisch partnerschap is aangegaan door middel van een ondersteunende investering van miljoenen dollars in IgniteData, een in het VK gevestigde digitale gezondheidsstartup die de toekomst van klinisch onderzoek vormgeeft door zijn Archer technologie.
Het doel van deze samenwerking is om de efficiëntie van klinisch onderzoek te verbeteren door middel van automatisering en het gebruik van real-world data, wat uiteindelijk de innovatie van farmaceutische producten en therapieën zal versnellen en de resultaten voor de patiënt zal verbeteren. Het partnerschap zal de interoperabiliteit tussen electronic health records (EHR) en kernonderzoekstoepassingen zoals electronic data capture (EDC) verbeteren om de efficiëntie van het verzamelen van patiëntgegevens voor onderzoeksinstellingen en sponsors in de context van klinisch onderzoek te verbeteren. Door de wereldwijde aanwezigheid van ZS zal het partnerschap zowel gezondheidssystemen als sponsors een bredere toegang geven tot dit soort onderzoek automatisering op wereldwijde schaal.
ZS and IgniteData Partner to Transform Patient Data Automation for Clinical Trials
EVANSTON, Ill.–(BUSINESS WIRE)– The global professional services firm ZS announced today that it has entered into a strategic partnership through a supporting multimillion dollar investment in IgniteData, a U.K.-based digital health startup shaping the future of clinical research through its Archer technology.
The goal for this partnership is to improve the efficiency of clinical research through automation and use of real-world data, which will ultimately expedite pharmaceutical product and therapy innovation and improve patient outcomes. The partnership will enhance interoperability between electronic health records (EHR) and core research applications such as electronic data capture (EDC) systems to improve the efficiency of patient data collection for research institutions and sponsors within the context of clinical research. Through ZS’s worldwide presence, the partnership will give both health systems and sponsors broader access to this type of research automation on a global scale.
“ZS’s vision is to transform what tomorrow’s research ecosystem looks like,” stated Pratap Khedkar, CEO of ZS. “We are committed to driving forward innovations that accelerate this transformation and enable better health outcomes for patients. This partnership is a step in that direction. IgniteData’s Archer application is a unique solution with enormous potential to accelerate clinical, medical and scientific innovations more broadly across healthcare and life sciences.”
IgniteData’s stand-alone Archer application acts as a virtual research assistant. Archer’s cloud-based HL7® FHIR® mapping engine identifies, imports, translates and transports regulatory-grade, clinically validated patient data from EHR systems already in place at research institutions to study sponsors for their enrolled patients. The application supports innovative evidence generation efforts through turnkey integrations with many major EHR and EDC systems such as Cerner, Epic, Castor and Medidata Rave, as well as through connections with other electronic systems that provide HL7® FHIR®-based APIs.
“IgniteData has been operating at the intersection of healthcare and clinical research for some time, and it is here, now more so than ever, that we believe the greatest opportunity exists to transform clinical trial delivery. Even though more than half of the data required for a trial already exists in the patients’ electronic medical records, this data is often manually transcribed into clinical trial systems, wasting huge staff resources as a result,” said Dan Hydes, CEO and co-founder of IgniteData. “Archer presents an incredible opportunity to improve the quality of trial operations by automating data extraction, eliminating human errors, reducing trial times and easing patient burden, ultimately helping to bring life-changing drugs to patients quicker. IgniteData is delighted to be in partnership with ZS on this mission.”
As an early adopter of Archer technology, Dr. Wai Keong Wong, chief research information officer at University College London Hospitals (UCLH), said, “We remain highly focused on harnessing our investment in Epic, our EHR, and progressing our data standardization initiatives to increase efficiency, reduce errors and free up valuable time for our highly trained research staff to support patients and other research participants. It’s a true-win-win for so many.” He continued, “Innovation is key for the National Institute for Health Research (NIHR) Biomedical Research Centre funded research centers such as UCLH, and we believe that partnerships should catalyze other healthcare organizations to digitize faster and adopt data standards, leading to richer, more dynamic and more impact-oriented research as a result.”
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 11,000-plus ZSers in 29 offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
IgniteData is the company shaping the future of clinical trials. Through its innovative digital health platform, Archer, it is enhancing interoperability between electronic health records (EHR) and key research applications such as electronic data capture (EDC). To learn more, visit IgniteData.co.uk.
UCLH (University College London Hospitals NHS Foundation Trust) provides first-class acute and specialist services in six hospitals in Central London.
UCLH hosts a National Institute for Health Research (NIHR) Biomedical Research Centre in partnership with UCL. By working together UCLH and UCL have become leaders in translating fundamental biomedical research into clinical research that benefits patients.
A key area of work is digital healthcare and enabling data-enabled trials in order to improve health through data.
The Bliss Group